Smith & Nephew plc reports news as a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. Coverage centers on Orthopaedics, Sports Medicine & ENT and Advanced Wound Management, including wound dressings, negative pressure wound therapy, cartilage and rotator cuff repair implants, orthopedic reconstruction, trauma and extremities products, and surgical robotics.
Recurring developments include product launches and clinical evidence for ALLEVYN COMPLETE CARE, RENASYS EDGE, CARTIHEAL AGILI-C, REGENETEN, CORI, AETOS and related platforms; conference showcases; distribution agreements; segment performance updates; share buybacks; and governance matters tied to the company’s London-listed shares and NYSE-traded ADRs.
Summary not available.
Summary not available.
Summary not available.
On April 24, 2023, Smith+Nephew (LSE:SN, NYSE:SNN) unveiled the CORI™ Digital Tensioner, a groundbreaking device designed for robotic-assisted knee surgeries. This innovative technology allows surgeons to measure ligament tension before bone cutting, enhancing surgical precision and reducing variability by 64% compared to manual methods. The tensioner provides quantifiable joint laxity data, facilitating better surgical planning. Dr. Steven Haas praised the device for its capability to deliver objective gap data, marking a significant advancement in knee replacement procedures. The first commercial use occurred in Arizona, highlighting its practical application in a clinical setting. This launch underscores Smith+Nephew's commitment to improving patient outcomes through innovative technologies.
On March 23, 2023, Smith+Nephew (NYSE:SNN) announced promising results from a meta-analysis of 17 studies involving over 6,500 patients, highlighting the effectiveness of its COBLATION Intracapsular Tonsillectomy (CIT) technique. The study reveals that CIT leads to significantly better post-operative outcomes compared to total tonsillectomy, including a 64% reduction in post-operative complications, shorter pain duration, and quicker recovery times. This innovative technique is gaining popularity among pediatric otolaryngologists, reflecting the company's commitment to improving surgical tools for better patient care.
Smith+Nephew (LSE:SN, NYSE:SNN) announced its participation in the American Academy of Orthopaedic Surgeons 2023 Annual Meeting in Las Vegas, showcasing innovative technologies in Sports Medicine. Key highlights include:
- UltraTRAC™ QUAD ACL Reconstruction Technique: Offers advanced solutions for ligament grafting.
- INTELLIO™ Tablet: A device for streamlined surgical connectivity.
- CAP-FIX™ Capsular Management Family: Enhances efficiency in capsular procedures.
- REGENETEN™ Bioinductive Implant: Promotes natural healing for tendon repair.
These products aim to improve surgical outcomes and patient recovery.
Smith+Nephew (LSE: SN, NYSE: SNN) announced its "Precision in Motion" initiative on March 7, 2023, during the AAOS 2023. This comprehensive strategy focuses on enhancing its Orthopaedics portfolio—Robotics, Knee, and Hip—by emphasizing personalizing surgery, advancing efficiency, and optimizing performance. The initiative is designed to improve surgical outcomes through advanced technology, including the first robotic revision indication in the US. With a commitment to delivering tailored solutions, Smith+Nephew aims to meet evolving needs in surgical practices while promising future investments in innovation.
Smith+Nephew (NYSE:SNN) has launched the UltraTRAC QUAD ACL Reconstruction Technique, featuring the QUADTRAC Quadriceps Tendon Harvest Guide System and ULTRABUTTON Adjustable Fixation Devices. These innovations aim to enhance procedural efficiency in ACL surgeries, which are projected to exceed 350,000 cases in the U.S. by 2023 with a 5.7% annual growth rate. The QUADTRAC System offers improved tendon visualization and controlled harvesting techniques, facilitating better surgical outcomes. This initiative reinforces Smith+Nephew's commitment to addressing surgeon preferences and expands its offerings within the sports medicine sector.
Smith+Nephew (NYSE: SNN) has released a systematic literature review and meta-analysis highlighting its VISIONAIRE Patient-Specific Instrumentation (PSI), which has shown enhanced alignment accuracy and efficiency in Total Knee Arthroplasty (TKA). The analysis included 25 studies, indicating significant improvements such as a 40% reduction in outlier odds for mechanical axis alignment, decreased operating room time, and an 11.1% reduction in hospital stay length. The findings, published in the Archives of Orthopaedic and Trauma Surgery, demonstrate that VISIONAIRE PSI leads to better patient outcomes and lower total hospital costs compared to conventional TKA methods.
Smith+Nephew (NYSE:SNN) announced that its LEAF Patient Monitoring System received an Innovative Technology designation from Vizient, the largest healthcare performance improvement company in the U.S. The award highlights products that enhance clinical care and safety. The LEAF System, the first wearable solution meeting NPIAP guidelines, has shown to improve adherence to patient turning protocols by 98% and reduce hospital-acquired pressure injuries by 73%. Its implementation resulted in estimated annual cost savings of up to $1.8 million in a critical care unit. Pressure injuries represent a rising hospital-acquired complication, costing roughly $11 billion in preventable treatments annually.